Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.
Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA. Martin-Castillo B, et al. Among authors: del barco s. Ann Oncol. 2010 Jan;21(1):187-9. doi: 10.1093/annonc/mdp494. Epub 2009 Nov 2. Ann Oncol. 2010. PMID: 19884247 Free article. No abstract available.
If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.
Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. Among authors: del barco s. J Clin Oncol. 2009 Nov 20;27(33):e207-9; author reply e210. doi: 10.1200/JCO.2009.24.5456. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858375 No abstract available.
Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA. Oliveras-Ferraros C, et al. Among authors: del barco s. Int J Oncol. 2010 Sep;37(3):669-78. doi: 10.3892/ijo_00000716. Int J Oncol. 2010. PMID: 20664936
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: del barco s. Int J Oncol. 2008 Dec;33(6):1165-76. Int J Oncol. 2008. PMID: 19020749
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Among authors: del barco s. Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041. Epub 2010 May 12. Biochem Biophys Res Commun. 2010. PMID: 20470755
54 results